This episode is a direct, data-rich briefing on a new damage-repair approach to atherosclerosis. Oki O'Connor of Cyclarity Therapeutics walks through the first-in-human Phase 1 results for their engineered cyclodextrin. The core problem is 7-ketocholesterol (7KC), an oxidized cholesterol derivative that accumulates in arterial plaque, driving inflammation and foam cell formation. Statins and PCSK9 inhibitors do not clear it. The solution is a specifically designed dimeric beta-cyclodextrin, shaped like a 'double cone,' that has high binding affinity and selectivity for 7KC over native cholesterol. The clinical data show a clear, dose-dependent increase in urinary 7KC excretion, providing direct pharmacodynamic proof of target engagement and clearance. The conversation covers the chemistry of the dimer design, the safety profile, and the specific math for funding a Phase 2 trial that will use plaque imaging as a primary endpoint. The discussion extends to the platform potential for other 7KC-driven diseases, including NASH, vascular dementia, and age-related macular degeneration. This is not a theoretical discussion; it is a grounded update on a therapy that aims to reverse a fundamental aging pathology.
Key Insights
- The drug is a dimeric beta-cyclodextrin 'double cone' engineered for high selectivity to 7-ketocholesterol over native cholesterol, solving an off-target toxicity problem.
- Phase 1 data demonstrated direct pharmacodynamic proof-of-mechanism via a dose-dependent increase of 7KC in urine, confirming the drug binds and clears the target from the body.
- 7-ketocholesterol is a causal, non-lipid driver of atherosclerosis that accumulates in plaque and is not removed by standard-of-care statins or PCSK9 inhibitors.
- The Phase 2 trial design is focused on plaque imaging endpoints to directly measure regression, with specific funding requirements and operational math discussed.
- The safety profile in Phase 1 was clean, with no significant off-target binding to native cholesterol, a critical de-risking event for the platform.
- The therapeutic platform extends beyond atherosclerosis to other 7KC-driven diseases like NASH, vascular dementia, and age-related macular degeneration.
Who should listen: Biotech investors and drug developers evaluating non-lipid, damage-repair mechanisms for atherosclerosis and other aging-related pathologies.
Why This Matters
This episode provides a concrete case study in moving a damage-repair therapeutic from concept to clinical proof-of-mechanism, a critical frontier for investors tracking the shift from disease management to reversal of age-related damage. The specific pharmacodynamic data and Phase 2 funding math offer a real-world template for evaluating other companies in the space.
